Drug intelligence / Profile preview

TQ-Z2301

Development stage: Unknown
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

TQ-Z2301 is a recombinant humanized monoclonal antibody developed by Jiangsu Chia Tai Tianqing Pharmaceutical as a biosimilar to secukinumab. It functions by specifically binding to and neutralizing interleukin-17A (IL-17A), a key pro-inflammatory cytokine that plays a central role in the pathogenesis of spondyloarthritides and plaque psoriasis. By blocking the interaction between IL-17A and its receptor, TQ-Z2301 inhibits the downstream release of inflammatory cytokines and chemokines, thereby reducing joint inflammation and skin lesions. It is currently in late-stage clinical development for the treatment of ankylosing spondylitis and moderate-to-severe plaque psoriasis.

Other names: secukinumab biosimilar

Targets

IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on TQ-Z2301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQ-Z2301.

Explore the full profile